171 filings
Page 4 of 9
6-K
nr5i 7bvcr
28 Jul 21
MediWound Announces Positive Outcome of Interim Assessment for its
7:05am
6-K
6ox 7ai7yrj3uz4kki
26 Jul 21
MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
7:05am
6-K
lsoqokg110c43p2zf
20 Jul 21
MediWound Announces Positive Topline Results from Phase 3 Pediatric
7:05am
6-K
bc7a44jxl
29 Jun 21
MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid
8:54am
6-K
9sbdxa1a rrm
15 Jun 21
Current report (foreign)
4:06pm
6-K
xuj59k
5 May 21
Current report (foreign)
4:15pm
6-K
jvy zezl40nd0nelj
5 May 21
MediWound Reports First Quarter 2021 Financial Results
7:05am
6-K
wkrt5psk
22 Apr 21
Current report (foreign)
7:39am
6-K
08ydzzdkqa6 uqza7l
25 Feb 21
MediWound Reports Fourth Quarter and Full-Year 2020 Financial Results
7:05am
6-K
qpace
22 Feb 21
MediWound Launches Clinical Development Program for Treatment of
6:30am
6-K
43mziiksj7nc y61hzwt
11 Jan 21
MediWound Provides Progress Update on Its EscharEx Clinical
7:05am
6-K
n85 2we6a718w
10 Nov 20
MediWound Reports Third Quarter 2020 Financial Results
7:06am
6-K
yvior74t
28 Oct 20
MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study
7:00am
6-K
kc7r g8hln4gnzlfgx
16 Sep 20
MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
7:35am
6-K
0rfeez
25 Aug 20
MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid
7:05am
6-K
lnrv0pzz154z065u 6eu
6 Aug 20
MediWound Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7:05am
6-K
0ithe
2 Jul 20
Current report (foreign)
4:05pm
6-K
ja7tk
30 Jun 20
MediWound Announces Submission of Biologics License Application to
7:05am
6-K
zhaty9
20 May 20
Current report (foreign)
4:15pm
6-K
j916eptuh
20 May 20
MediWound Reports First Quarter 2020 Financial Results and Provides Corporate Update
7:05am